Bixiye
P19-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Natiijooyinka Raadinta
Soo bandhiga 1811 - 1820 ee natiijooyinka 3688
Bixiye
2022 April Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Faa'iidooyinka & Caymiska
Blue Plus 2022 Formulary
Bixiye
Tavneos™ (avacopan) - Commercial
Prior Authorization, Quantity Limit
Taariikhda barnaamijka Dhaqangalayso Agosto 01, 2024
Bixiye
Xhance® (fluticasone propionate) - Commercial
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2025
Bixiye
VMAT2 Inhibitors (Vesicular Monoamine Transporter 2) - Medicaid - Effective Date 03/01/2025
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2025
Bixiye
P23-22 eviCore Healthcare Specialty Utilization Management (UM) Program - Cardiology and Radiology Clinical Guideline Updates
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
P24-22 Update: eviCore Healthcare Specialty Utilization Management (UM) Program – Medical Oncology Drug Prior Authorization Updates
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
QP29-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: TavneosTM (avacopan)
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 13, 2022
Bixiye
QP30-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: TyrvayaTM (varenicline)
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 13, 2022